ProQR Therapeutics (PRQR) Other Accumulated Expenses (2013 - 2023)

ProQR Therapeutics has disclosed Other Accumulated Expenses across 11 years of filings, most recently posting $5.2 million for Q3 2023.

• Other Accumulated Expenses for Q3 2023 came in at $5.2 million, down 62.05% year-over-year; the trailing twelve-month figure through Sep 2023 was $5.2 million (down 62.05% YoY), and the FY2022 annual result was $8.9 million, down 30.4% from the prior year.
• Other Accumulated Expenses came in at $5.2 million for Q3 2023 at ProQR Therapeutics, up from $4.4 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $13.8 million in Q3 2022 to a low of $9.49 in Q1 2019.
• The 5-year median for Other Accumulated Expenses is $7.8 million (2020), against an average of $7.5 million.
• Across the five-year window, Other Accumulated Expenses surged 124844949.54% in 2019 and tumbled 99.92% in 2021, its largest moves.
• ProQR Therapeutics' Other Accumulated Expenses stood at $9.8 million in 2019, then declined by 25.22% to $7.3 million in 2020, then jumped by 68.75% to $12.3 million in 2021, then slipped by 28.0% to $8.9 million in 2022, then plunged by 40.87% to $5.2 million in 2023.
• The last three Other Accumulated Expenses figures came in at $5.2 million (Q3 2023), $4.4 million (Q2 2023), and $5.3 million (Q1 2023), per Business Quant data.